nodes	percent_of_prediction	percent_of_DWPC	metapath
Cysteamine—SST—thyroid cancer	0.875	1	CbGaD
Cysteamine—NPY2R—head—thyroid cancer	0.00744	0.26	CbGeAlD
Cysteamine—SST—neck—thyroid cancer	0.00688	0.24	CbGeAlD
Cysteamine—SST—trachea—thyroid cancer	0.00414	0.144	CbGeAlD
Cysteamine—SST—thyroid gland—thyroid cancer	0.00328	0.114	CbGeAlD
Cysteamine—SST—head—thyroid cancer	0.00291	0.101	CbGeAlD
Cysteamine—Cerebral ischaemia—Vandetanib—thyroid cancer	0.00284	0.0494	CcSEcCtD
Cysteamine—NPY2R—Peptide GPCRs—TSHR—thyroid cancer	0.00266	0.0679	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—RET—thyroid cancer	0.00243	0.0621	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.00226	0.0577	CbGpPWpGaD
Cysteamine—SST—lymph node—thyroid cancer	0.00204	0.071	CbGeAlD
Cysteamine—Nephrotic syndrome—Sorafenib—thyroid cancer	0.00192	0.0334	CcSEcCtD
Cysteamine—NPY2R—Circadian rythm related genes—NKX2-1—thyroid cancer	0.00186	0.0473	CbGpPWpGaD
Cysteamine—Tubulointerstitial nephritis—Vandetanib—thyroid cancer	0.00179	0.0312	CcSEcCtD
Cysteamine—SST—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.0015	0.0383	CbGpPWpGaD
Cysteamine—SST—GPCR ligand binding—CALCB—thyroid cancer	0.00144	0.0367	CbGpPWpGaD
Cysteamine—NPY2R—GPCR ligand binding—CALCB—thyroid cancer	0.00138	0.0352	CbGpPWpGaD
Cysteamine—Tubulointerstitial nephritis—Sorafenib—thyroid cancer	0.00121	0.021	CcSEcCtD
Cysteamine—MPO—head—thyroid cancer	0.00117	0.0408	CbGeAlD
Cysteamine—Gastroenteritis—Vandetanib—thyroid cancer	0.00112	0.0196	CcSEcCtD
Cysteamine—Bone disorder—Sorafenib—thyroid cancer	0.00103	0.0178	CcSEcCtD
Cysteamine—Lethargy—Vandetanib—thyroid cancer	0.00102	0.0177	CcSEcCtD
Cysteamine—NPY2R—Peptide ligand-binding receptors—SST—thyroid cancer	0.000974	0.0248	CbGpPWpGaD
Cysteamine—Dehydration—Vandetanib—thyroid cancer	0.000927	0.0161	CcSEcCtD
Cysteamine—SST—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.000876	0.0223	CbGpPWpGaD
Cysteamine—NPY2R—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00084	0.0214	CbGpPWpGaD
Cysteamine—NPY2R—G alpha (i) signalling events—SST—thyroid cancer	0.000821	0.0209	CbGpPWpGaD
Cysteamine—MPO—lymph node—thyroid cancer	0.00082	0.0286	CbGeAlD
Cysteamine—SST—GPCR downstream signaling—CALCB—thyroid cancer	0.000814	0.0208	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—CALCB—thyroid cancer	0.000781	0.0199	CbGpPWpGaD
Cysteamine—Hepatic function abnormal—Sorafenib—thyroid cancer	0.000769	0.0134	CcSEcCtD
Cysteamine—Renal failure—Vandetanib—thyroid cancer	0.000755	0.0131	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—CALCB—thyroid cancer	0.000739	0.0188	CbGpPWpGaD
Cysteamine—SST—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000714	0.0182	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—CALCB—thyroid cancer	0.000709	0.0181	CbGpPWpGaD
Cysteamine—Urinary tract disorder—Vandetanib—thyroid cancer	0.000681	0.0119	CcSEcCtD
Cysteamine—Urethral disorder—Vandetanib—thyroid cancer	0.000676	0.0118	CcSEcCtD
Cysteamine—Pain in extremity—Sorafenib—thyroid cancer	0.000672	0.0117	CcSEcCtD
Cysteamine—SST—GPCR ligand binding—TSHR—thyroid cancer	0.000667	0.017	CbGpPWpGaD
Cysteamine—NPY2R—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.000653	0.0166	CbGpPWpGaD
Cysteamine—NPY2R—GPCR ligand binding—TSHR—thyroid cancer	0.000639	0.0163	CbGpPWpGaD
Cysteamine—Mood swings—Sorafenib—thyroid cancer	0.000637	0.0111	CcSEcCtD
Cysteamine—Dehydration—Sorafenib—thyroid cancer	0.000625	0.0109	CcSEcCtD
Cysteamine—Mental disorder—Vandetanib—thyroid cancer	0.000604	0.0105	CcSEcCtD
Cysteamine—Malnutrition—Vandetanib—thyroid cancer	0.0006	0.0104	CcSEcCtD
Cysteamine—SST—GPCR ligand binding—PTCH1—thyroid cancer	0.000567	0.0145	CbGpPWpGaD
Cysteamine—Tremor—Vandetanib—thyroid cancer	0.000562	0.00979	CcSEcCtD
Cysteamine—Optic neuritis—Epirubicin—thyroid cancer	0.000557	0.00968	CcSEcCtD
Cysteamine—NPY2R—GPCR ligand binding—PTCH1—thyroid cancer	0.000544	0.0139	CbGpPWpGaD
Cysteamine—Convulsion—Vandetanib—thyroid cancer	0.00052	0.00905	CcSEcCtD
Cysteamine—Hypertension—Vandetanib—thyroid cancer	0.000518	0.00902	CcSEcCtD
Cysteamine—Optic neuritis—Doxorubicin—thyroid cancer	0.000515	0.00896	CcSEcCtD
Cysteamine—Renal failure—Sorafenib—thyroid cancer	0.000509	0.00886	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.000508	0.00883	CcSEcCtD
Cysteamine—Redness—Epirubicin—thyroid cancer	0.000507	0.00882	CcSEcCtD
Cysteamine—SST—GPCR ligand binding—CALCA—thyroid cancer	0.000499	0.0127	CbGpPWpGaD
Cysteamine—NPY2R—GPCR ligand binding—SST—thyroid cancer	0.000497	0.0127	CbGpPWpGaD
Cysteamine—Nervous system disorder—Vandetanib—thyroid cancer	0.00048	0.00836	CcSEcCtD
Cysteamine—NPY2R—GPCR ligand binding—CALCA—thyroid cancer	0.000479	0.0122	CbGpPWpGaD
Cysteamine—Skin disorder—Vandetanib—thyroid cancer	0.000476	0.00828	CcSEcCtD
Cysteamine—NPY2R—Circadian rythm related genes—PPARG—thyroid cancer	0.000475	0.0121	CbGpPWpGaD
Cysteamine—Redness—Doxorubicin—thyroid cancer	0.000469	0.00816	CcSEcCtD
Cysteamine—Urinary tract disorder—Sorafenib—thyroid cancer	0.000459	0.00799	CcSEcCtD
Cysteamine—Connective tissue disorder—Sorafenib—thyroid cancer	0.000457	0.00795	CcSEcCtD
Cysteamine—Urethral disorder—Sorafenib—thyroid cancer	0.000456	0.00793	CcSEcCtD
Cysteamine—Scotoma—Epirubicin—thyroid cancer	0.000451	0.00784	CcSEcCtD
Cysteamine—SST—Signaling Pathways—CALCB—thyroid cancer	0.000437	0.0111	CbGpPWpGaD
Cysteamine—Dyspepsia—Vandetanib—thyroid cancer	0.000431	0.0075	CcSEcCtD
Cysteamine—Decreased appetite—Vandetanib—thyroid cancer	0.000426	0.00741	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000423	0.00736	CcSEcCtD
Cysteamine—Fatigue—Vandetanib—thyroid cancer	0.000422	0.00735	CcSEcCtD
Cysteamine—Immune system disorder—Sorafenib—thyroid cancer	0.00042	0.00731	CcSEcCtD
Cysteamine—Constipation—Vandetanib—thyroid cancer	0.000419	0.00729	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—CALCB—thyroid cancer	0.000419	0.0107	CbGpPWpGaD
Cysteamine—Scotoma—Doxorubicin—thyroid cancer	0.000417	0.00726	CcSEcCtD
Cysteamine—SST—Signaling Pathways—TRIM33—thyroid cancer	0.000414	0.0106	CbGpPWpGaD
Cysteamine—Mental disorder—Sorafenib—thyroid cancer	0.000408	0.00709	CcSEcCtD
Cysteamine—Erythema—Sorafenib—thyroid cancer	0.000405	0.00705	CcSEcCtD
Cysteamine—Malnutrition—Sorafenib—thyroid cancer	0.000405	0.00705	CcSEcCtD
Cysteamine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000401	0.00697	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—TRIM33—thyroid cancer	0.000397	0.0101	CbGpPWpGaD
Cysteamine—Body temperature increased—Vandetanib—thyroid cancer	0.000387	0.00674	CcSEcCtD
Cysteamine—Abdominal pain—Vandetanib—thyroid cancer	0.000387	0.00674	CcSEcCtD
Cysteamine—Bone disorder—Epirubicin—thyroid cancer	0.000379	0.0066	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—TSHR—thyroid cancer	0.000377	0.00961	CbGpPWpGaD
Cysteamine—Anaemia—Sorafenib—thyroid cancer	0.000374	0.00651	CcSEcCtD
Cysteamine—Thinking abnormal—Epirubicin—thyroid cancer	0.000374	0.00651	CcSEcCtD
Cysteamine—Leukopenia—Sorafenib—thyroid cancer	0.000362	0.00631	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—TSHR—thyroid cancer	0.000361	0.00921	CbGpPWpGaD
Cysteamine—Asthenia—Vandetanib—thyroid cancer	0.000351	0.00612	CcSEcCtD
Cysteamine—Bone disorder—Doxorubicin—thyroid cancer	0.000351	0.0061	CcSEcCtD
Cysteamine—Hypertension—Sorafenib—thyroid cancer	0.00035	0.00608	CcSEcCtD
Cysteamine—Thinking abnormal—Doxorubicin—thyroid cancer	0.000346	0.00602	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000342	0.00596	CcSEcCtD
Cysteamine—Phosphatase alkaline increased—Epirubicin—thyroid cancer	0.000342	0.00596	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—TSHR—thyroid cancer	0.000342	0.00873	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000337	0.00858	CbGpPWpGaD
Cysteamine—Diarrhoea—Vandetanib—thyroid cancer	0.000335	0.00583	CcSEcCtD
Cysteamine—Anaphylactic shock—Sorafenib—thyroid cancer	0.00033	0.00575	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—TSHR—thyroid cancer	0.000328	0.00837	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—PTEN—thyroid cancer	0.000326	0.00831	CbGpPWpGaD
Cysteamine—Nervous system disorder—Sorafenib—thyroid cancer	0.000324	0.00564	CcSEcCtD
Cysteamine—Dizziness—Vandetanib—thyroid cancer	0.000324	0.00564	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000323	0.00823	CbGpPWpGaD
Cysteamine—Skin disorder—Sorafenib—thyroid cancer	0.000321	0.00559	CcSEcCtD
Cysteamine—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	0.000317	0.00551	CcSEcCtD
Cysteamine—Anorexia—Sorafenib—thyroid cancer	0.000315	0.00548	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—PTGS2—thyroid cancer	0.000312	0.00795	CbGpPWpGaD
Cysteamine—Vomiting—Vandetanib—thyroid cancer	0.000311	0.00542	CcSEcCtD
Cysteamine—Rash—Vandetanib—thyroid cancer	0.000309	0.00538	CcSEcCtD
Cysteamine—Dermatitis—Vandetanib—thyroid cancer	0.000309	0.00537	CcSEcCtD
Cysteamine—Headache—Vandetanib—thyroid cancer	0.000307	0.00534	CcSEcCtD
Cysteamine—MPO—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000301	0.00766	CbGpPWpGaD
Cysteamine—Mental disability—Epirubicin—thyroid cancer	0.000297	0.00517	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—PTCH1—thyroid cancer	0.000291	0.00742	CbGpPWpGaD
Cysteamine—Nausea—Vandetanib—thyroid cancer	0.000291	0.00506	CcSEcCtD
Cysteamine—Dyspepsia—Sorafenib—thyroid cancer	0.000291	0.00506	CcSEcCtD
Cysteamine—Decreased appetite—Sorafenib—thyroid cancer	0.000287	0.005	CcSEcCtD
Cysteamine—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.000286	0.00497	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000285	0.00496	CcSEcCtD
Cysteamine—Fatigue—Sorafenib—thyroid cancer	0.000285	0.00496	CcSEcCtD
Cysteamine—Hepatic function abnormal—Epirubicin—thyroid cancer	0.000284	0.00495	CcSEcCtD
Cysteamine—Constipation—Sorafenib—thyroid cancer	0.000283	0.00492	CcSEcCtD
Cysteamine—SST—GPCR downstream signaling—CALCA—thyroid cancer	0.000282	0.00719	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—CCND1—thyroid cancer	0.000282	0.00719	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—SST—thyroid cancer	0.000281	0.00716	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—PTCH1—thyroid cancer	0.000279	0.00711	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—TCF7L1—thyroid cancer	0.000276	0.00704	CbGpPWpGaD
Cysteamine—Eye pain—Epirubicin—thyroid cancer	0.000275	0.00479	CcSEcCtD
Cysteamine—Mental disability—Doxorubicin—thyroid cancer	0.000275	0.00478	CcSEcCtD
Cysteamine—NPY2R—GPCR downstream signaling—CALCA—thyroid cancer	0.000271	0.0069	CbGpPWpGaD
Cysteamine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00027	0.0047	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—TCF7L1—thyroid cancer	0.000265	0.00675	CbGpPWpGaD
Cysteamine—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.000264	0.0046	CcSEcCtD
Cysteamine—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.000263	0.00458	CcSEcCtD
Cysteamine—Urticaria—Sorafenib—thyroid cancer	0.000263	0.00457	CcSEcCtD
Cysteamine—Body temperature increased—Sorafenib—thyroid cancer	0.000261	0.00455	CcSEcCtD
Cysteamine—Abdominal pain—Sorafenib—thyroid cancer	0.000261	0.00455	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—CALCA—thyroid cancer	0.000256	0.00653	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—SST—thyroid cancer	0.000255	0.00651	CbGpPWpGaD
Cysteamine—Eye pain—Doxorubicin—thyroid cancer	0.000255	0.00443	CcSEcCtD
Cysteamine—Lethargy—Epirubicin—thyroid cancer	0.000254	0.00441	CcSEcCtD
Cysteamine—Pain in extremity—Epirubicin—thyroid cancer	0.000248	0.00432	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—CALCA—thyroid cancer	0.000246	0.00626	CbGpPWpGaD
Cysteamine—Affect lability—Epirubicin—thyroid cancer	0.000245	0.00426	CcSEcCtD
Cysteamine—Hypersensitivity—Sorafenib—thyroid cancer	0.000243	0.00424	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—NRAS—thyroid cancer	0.000243	0.00619	CbGpPWpGaD
Cysteamine—Asthenia—Sorafenib—thyroid cancer	0.000237	0.00413	CcSEcCtD
Cysteamine—Mood swings—Epirubicin—thyroid cancer	0.000235	0.0041	CcSEcCtD
Cysteamine—Lethargy—Doxorubicin—thyroid cancer	0.000235	0.00408	CcSEcCtD
Cysteamine—Ataxia—Epirubicin—thyroid cancer	0.000234	0.00407	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—CDK1—thyroid cancer	0.000232	0.00591	CbGpPWpGaD
Cysteamine—Dehydration—Epirubicin—thyroid cancer	0.000231	0.00402	CcSEcCtD
Cysteamine—Pain in extremity—Doxorubicin—thyroid cancer	0.00023	0.004	CcSEcCtD
Cysteamine—Liver function test abnormal—Epirubicin—thyroid cancer	0.000229	0.00399	CcSEcCtD
Cysteamine—Affect lability—Doxorubicin—thyroid cancer	0.000226	0.00394	CcSEcCtD
Cysteamine—Diarrhoea—Sorafenib—thyroid cancer	0.000226	0.00393	CcSEcCtD
Cysteamine—MPO—Folate Metabolism—TP53—thyroid cancer	0.000225	0.00574	CbGpPWpGaD
Cysteamine—NPY2R—Circadian rythm related genes—TP53—thyroid cancer	0.000223	0.00567	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—CDK1—thyroid cancer	0.000222	0.00567	CbGpPWpGaD
Cysteamine—Dizziness—Sorafenib—thyroid cancer	0.000219	0.0038	CcSEcCtD
Cysteamine—Mood swings—Doxorubicin—thyroid cancer	0.000218	0.00379	CcSEcCtD
Cysteamine—Ataxia—Doxorubicin—thyroid cancer	0.000216	0.00376	CcSEcCtD
Cysteamine—Dehydration—Doxorubicin—thyroid cancer	0.000214	0.00372	CcSEcCtD
Cysteamine—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000212	0.00369	CcSEcCtD
Cysteamine—Vomiting—Sorafenib—thyroid cancer	0.00021	0.00366	CcSEcCtD
Cysteamine—MPO—C-MYB transcription factor network—KRAS—thyroid cancer	0.000209	0.00533	CbGpPWpGaD
Cysteamine—Rash—Sorafenib—thyroid cancer	0.000208	0.00363	CcSEcCtD
Cysteamine—Dermatitis—Sorafenib—thyroid cancer	0.000208	0.00362	CcSEcCtD
Cysteamine—Headache—Sorafenib—thyroid cancer	0.000207	0.0036	CcSEcCtD
Cysteamine—SST—Signaling Pathways—TSHR—thyroid cancer	0.000202	0.00515	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PRKAR1A—thyroid cancer	0.000199	0.00507	CbGpPWpGaD
Cysteamine—Nausea—Sorafenib—thyroid cancer	0.000196	0.00342	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—TSHR—thyroid cancer	0.000194	0.00494	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PRKAR1A—thyroid cancer	0.000191	0.00486	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—MEN1—thyroid cancer	0.00019	0.00485	CbGpPWpGaD
Cysteamine—Renal failure—Epirubicin—thyroid cancer	0.000188	0.00328	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—MEN1—thyroid cancer	0.000182	0.00465	CbGpPWpGaD
Cysteamine—MPO—C-MYB transcription factor network—HRAS—thyroid cancer	0.000178	0.00453	CbGpPWpGaD
Cysteamine—Renal failure—Doxorubicin—thyroid cancer	0.000174	0.00303	CcSEcCtD
Cysteamine—SST—Signaling Pathways—PTCH1—thyroid cancer	0.000172	0.00438	CbGpPWpGaD
Cysteamine—Urinary tract disorder—Epirubicin—thyroid cancer	0.00017	0.00295	CcSEcCtD
Cysteamine—Connective tissue disorder—Epirubicin—thyroid cancer	0.000169	0.00294	CcSEcCtD
Cysteamine—Urethral disorder—Epirubicin—thyroid cancer	0.000169	0.00293	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—PTCH1—thyroid cancer	0.000165	0.0042	CbGpPWpGaD
Cysteamine—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000157	0.00273	CcSEcCtD
Cysteamine—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000156	0.00272	CcSEcCtD
Cysteamine—Urethral disorder—Doxorubicin—thyroid cancer	0.000156	0.00271	CcSEcCtD
Cysteamine—Immune system disorder—Epirubicin—thyroid cancer	0.000155	0.0027	CcSEcCtD
Cysteamine—SST—Signaling Pathways—CALCA—thyroid cancer	0.000151	0.00386	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—SST—thyroid cancer	0.000151	0.00384	CbGpPWpGaD
Cysteamine—Mental disorder—Epirubicin—thyroid cancer	0.000151	0.00262	CcSEcCtD
Cysteamine—Erythema—Epirubicin—thyroid cancer	0.00015	0.0026	CcSEcCtD
Cysteamine—Malnutrition—Epirubicin—thyroid cancer	0.00015	0.0026	CcSEcCtD
Cysteamine—Tension—Epirubicin—thyroid cancer	0.000147	0.00256	CcSEcCtD
Cysteamine—Nervousness—Epirubicin—thyroid cancer	0.000145	0.00253	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—CALCA—thyroid cancer	0.000145	0.0037	CbGpPWpGaD
Cysteamine—Immune system disorder—Doxorubicin—thyroid cancer	0.000144	0.0025	CcSEcCtD
Cysteamine—Mental disorder—Doxorubicin—thyroid cancer	0.000139	0.00242	CcSEcCtD
Cysteamine—Erythema—Doxorubicin—thyroid cancer	0.000138	0.00241	CcSEcCtD
Cysteamine—Malnutrition—Doxorubicin—thyroid cancer	0.000138	0.00241	CcSEcCtD
Cysteamine—Anaemia—Epirubicin—thyroid cancer	0.000138	0.00241	CcSEcCtD
Cysteamine—Agitation—Epirubicin—thyroid cancer	0.000138	0.00239	CcSEcCtD
Cysteamine—SST—Signaling Pathways—CDK1—thyroid cancer	0.000137	0.00349	CbGpPWpGaD
Cysteamine—Tension—Doxorubicin—thyroid cancer	0.000136	0.00236	CcSEcCtD
Cysteamine—Nervousness—Doxorubicin—thyroid cancer	0.000134	0.00234	CcSEcCtD
Cysteamine—Leukopenia—Epirubicin—thyroid cancer	0.000134	0.00233	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—CDK1—thyroid cancer	0.000131	0.00335	CbGpPWpGaD
Cysteamine—Convulsion—Epirubicin—thyroid cancer	0.00013	0.00226	CcSEcCtD
Cysteamine—Hypertension—Epirubicin—thyroid cancer	0.000129	0.00225	CcSEcCtD
Cysteamine—Anaemia—Doxorubicin—thyroid cancer	0.000128	0.00223	CcSEcCtD
Cysteamine—Agitation—Doxorubicin—thyroid cancer	0.000127	0.00221	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000127	0.0022	CcSEcCtD
Cysteamine—Discomfort—Epirubicin—thyroid cancer	0.000126	0.00219	CcSEcCtD
Cysteamine—Leukopenia—Doxorubicin—thyroid cancer	0.000124	0.00216	CcSEcCtD
Cysteamine—Confusional state—Epirubicin—thyroid cancer	0.000123	0.00214	CcSEcCtD
Cysteamine—Anaphylactic shock—Epirubicin—thyroid cancer	0.000122	0.00213	CcSEcCtD
Cysteamine—Convulsion—Doxorubicin—thyroid cancer	0.00012	0.00209	CcSEcCtD
Cysteamine—Nervous system disorder—Epirubicin—thyroid cancer	0.00012	0.00208	CcSEcCtD
Cysteamine—Hypertension—Doxorubicin—thyroid cancer	0.00012	0.00208	CcSEcCtD
Cysteamine—Skin disorder—Epirubicin—thyroid cancer	0.000119	0.00206	CcSEcCtD
Cysteamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000117	0.00204	CcSEcCtD
Cysteamine—Discomfort—Doxorubicin—thyroid cancer	0.000116	0.00203	CcSEcCtD
Cysteamine—Anorexia—Epirubicin—thyroid cancer	0.000116	0.00203	CcSEcCtD
Cysteamine—Confusional state—Doxorubicin—thyroid cancer	0.000114	0.00198	CcSEcCtD
Cysteamine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000113	0.00197	CcSEcCtD
Cysteamine—Nervous system disorder—Doxorubicin—thyroid cancer	0.000111	0.00193	CcSEcCtD
Cysteamine—SST—Signaling Pathways—NRG1—thyroid cancer	0.00011	0.0028	CbGpPWpGaD
Cysteamine—Skin disorder—Doxorubicin—thyroid cancer	0.00011	0.00191	CcSEcCtD
Cysteamine—Somnolence—Epirubicin—thyroid cancer	0.000109	0.00189	CcSEcCtD
Cysteamine—Anorexia—Doxorubicin—thyroid cancer	0.000108	0.00187	CcSEcCtD
Cysteamine—Dyspepsia—Epirubicin—thyroid cancer	0.000108	0.00187	CcSEcCtD
Cysteamine—Decreased appetite—Epirubicin—thyroid cancer	0.000106	0.00185	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000105	0.00183	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—NRG1—thyroid cancer	0.000105	0.00269	CbGpPWpGaD
Cysteamine—Fatigue—Epirubicin—thyroid cancer	0.000105	0.00183	CcSEcCtD
Cysteamine—Constipation—Epirubicin—thyroid cancer	0.000104	0.00182	CcSEcCtD
Cysteamine—Feeling abnormal—Epirubicin—thyroid cancer	0.000101	0.00175	CcSEcCtD
Cysteamine—Somnolence—Doxorubicin—thyroid cancer	0.0001	0.00175	CcSEcCtD
Cysteamine—Gastrointestinal pain—Epirubicin—thyroid cancer	9.99e-05	0.00174	CcSEcCtD
Cysteamine—Dyspepsia—Doxorubicin—thyroid cancer	9.95e-05	0.00173	CcSEcCtD
Cysteamine—SST—Signaling Pathways—TERT—thyroid cancer	9.87e-05	0.00252	CbGpPWpGaD
Cysteamine—Decreased appetite—Doxorubicin—thyroid cancer	9.82e-05	0.00171	CcSEcCtD
Cysteamine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	9.76e-05	0.0017	CcSEcCtD
Cysteamine—Fatigue—Doxorubicin—thyroid cancer	9.74e-05	0.0017	CcSEcCtD
Cysteamine—Urticaria—Epirubicin—thyroid cancer	9.7e-05	0.00169	CcSEcCtD
Cysteamine—Constipation—Doxorubicin—thyroid cancer	9.66e-05	0.00168	CcSEcCtD
Cysteamine—Abdominal pain—Epirubicin—thyroid cancer	9.65e-05	0.00168	CcSEcCtD
Cysteamine—Body temperature increased—Epirubicin—thyroid cancer	9.65e-05	0.00168	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—TERT—thyroid cancer	9.47e-05	0.00241	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—HIF1A—thyroid cancer	9.44e-05	0.00241	CbGpPWpGaD
Cysteamine—Feeling abnormal—Doxorubicin—thyroid cancer	9.31e-05	0.00162	CcSEcCtD
Cysteamine—Gastrointestinal pain—Doxorubicin—thyroid cancer	9.24e-05	0.00161	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—HIF1A—thyroid cancer	9.05e-05	0.00231	CbGpPWpGaD
Cysteamine—Hypersensitivity—Epirubicin—thyroid cancer	9e-05	0.00157	CcSEcCtD
Cysteamine—Urticaria—Doxorubicin—thyroid cancer	8.98e-05	0.00156	CcSEcCtD
Cysteamine—Abdominal pain—Doxorubicin—thyroid cancer	8.93e-05	0.00155	CcSEcCtD
Cysteamine—Body temperature increased—Doxorubicin—thyroid cancer	8.93e-05	0.00155	CcSEcCtD
Cysteamine—Asthenia—Epirubicin—thyroid cancer	8.76e-05	0.00152	CcSEcCtD
Cysteamine—Diarrhoea—Epirubicin—thyroid cancer	8.36e-05	0.00145	CcSEcCtD
Cysteamine—Hypersensitivity—Doxorubicin—thyroid cancer	8.33e-05	0.00145	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—NRAS—thyroid cancer	8.32e-05	0.00212	CbGpPWpGaD
Cysteamine—Asthenia—Doxorubicin—thyroid cancer	8.11e-05	0.00141	CcSEcCtD
Cysteamine—Dizziness—Epirubicin—thyroid cancer	8.08e-05	0.00141	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—NRAS—thyroid cancer	7.98e-05	0.00203	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—BRAF—thyroid cancer	7.82e-05	0.00199	CbGpPWpGaD
Cysteamine—Vomiting—Epirubicin—thyroid cancer	7.77e-05	0.00135	CcSEcCtD
Cysteamine—Diarrhoea—Doxorubicin—thyroid cancer	7.73e-05	0.00135	CcSEcCtD
Cysteamine—Rash—Epirubicin—thyroid cancer	7.7e-05	0.00134	CcSEcCtD
Cysteamine—Dermatitis—Epirubicin—thyroid cancer	7.69e-05	0.00134	CcSEcCtD
Cysteamine—Headache—Epirubicin—thyroid cancer	7.65e-05	0.00133	CcSEcCtD
Cysteamine—NPY2R—Signaling Pathways—BRAF—thyroid cancer	7.5e-05	0.00191	CbGpPWpGaD
Cysteamine—Dizziness—Doxorubicin—thyroid cancer	7.47e-05	0.0013	CcSEcCtD
Cysteamine—Nausea—Epirubicin—thyroid cancer	7.25e-05	0.00126	CcSEcCtD
Cysteamine—Vomiting—Doxorubicin—thyroid cancer	7.19e-05	0.00125	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—KRAS—thyroid cancer	7.16e-05	0.00183	CbGpPWpGaD
Cysteamine—Rash—Doxorubicin—thyroid cancer	7.13e-05	0.00124	CcSEcCtD
Cysteamine—Dermatitis—Doxorubicin—thyroid cancer	7.12e-05	0.00124	CcSEcCtD
Cysteamine—Headache—Doxorubicin—thyroid cancer	7.08e-05	0.00123	CcSEcCtD
Cysteamine—NPY2R—Signaling by GPCR—KRAS—thyroid cancer	6.86e-05	0.00175	CbGpPWpGaD
Cysteamine—Nausea—Doxorubicin—thyroid cancer	6.71e-05	0.00117	CcSEcCtD
Cysteamine—SST—Signaling by GPCR—HRAS—thyroid cancer	6.09e-05	0.00155	CbGpPWpGaD
Cysteamine—SST—GPCR downstream signaling—AKT1—thyroid cancer	5.92e-05	0.00151	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—HRAS—thyroid cancer	5.84e-05	0.00149	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—CCND1—thyroid cancer	5.71e-05	0.00145	CbGpPWpGaD
Cysteamine—NPY2R—GPCR downstream signaling—AKT1—thyroid cancer	5.67e-05	0.00145	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—PTEN—thyroid cancer	5.51e-05	0.0014	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—CCND1—thyroid cancer	5.47e-05	0.00139	CbGpPWpGaD
Cysteamine—SST—Signaling by GPCR—AKT1—thyroid cancer	5.37e-05	0.00137	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—PTEN—thyroid cancer	5.28e-05	0.00135	CbGpPWpGaD
Cysteamine—NPY2R—Signaling by GPCR—AKT1—thyroid cancer	5.15e-05	0.00131	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—NRAS—thyroid cancer	4.91e-05	0.00125	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—NRAS—thyroid cancer	4.71e-05	0.0012	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—KRAS—thyroid cancer	4.23e-05	0.00108	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—KRAS—thyroid cancer	4.06e-05	0.00103	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—TP53—thyroid cancer	3.76e-05	0.000958	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—TP53—thyroid cancer	3.6e-05	0.000919	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—HRAS—thyroid cancer	3.6e-05	0.000917	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—HRAS—thyroid cancer	3.45e-05	0.000879	CbGpPWpGaD
Cysteamine—SST—Signaling Pathways—AKT1—thyroid cancer	3.17e-05	0.000809	CbGpPWpGaD
Cysteamine—NPY2R—Signaling Pathways—AKT1—thyroid cancer	3.04e-05	0.000776	CbGpPWpGaD
